Substance use histories in patients seeking treatment for controlled-release oxycodone dependence

被引:44
作者
Potter, JS
Hennessy, G
Borrow, JA
Greenfield, SF
Weiss, RD
机构
[1] McLean Hosp, Belmont, MA 02478 USA
[2] Harvard Univ, Sch Med, Belmont, MA 02478 USA
关键词
prescription opiate abuse; oxycodone; pain patients;
D O I
10.1016/j.drugalcdep.2004.05.001
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The characteristics of patients currently abusing control led-release (CR) oxycodone admitted for inpatient detoxification were ascertained from medical record review of 48 inpatients with CR oxycodone dependence. Patients were categorized according to the manner in which they initially received the drug: illicitly or by prescription for legitimate medical use. Fifteen of the 48 patients (31%) initially obtained a CR oxycodone prescription legitimately for a medical condition. While none of these 15 patients had a history of prior opioid misuse, they were more likely than illicit CR oxycodone users to report prior detoxifications (P < 0.03) as well as a lower mean age of first alcohol use (legitimate = 11.7 versus illicit = 14.7, P < 0.05) and first illicit drug use (legitimate = 12.8 versus illicit = 15.8, P < 0.05). These findings suggest that a history of substance abuse is common among patients abusing CR oxycodone, including individuals for whom CR oxycodone was initially legitimately prescribed for pain. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:213 / 215
页数:3
相关论文
共 50 条
  • [21] Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?
    Bruce Charles
    Janet Hardy
    Helen Anderson
    Angela Tapuni
    Rani George
    Ross Norris
    Supportive Care in Cancer, 2014, 22 : 325 - 330
  • [22] Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?
    Charles, Bruce
    Hardy, Janet
    Anderson, Helen
    Tapuni, Angela
    George, Rani
    Norris, Ross
    SUPPORTIVE CARE IN CANCER, 2014, 22 (02) : 325 - 330
  • [23] Conversion to oral controlled-release oxycodone from intravenous opioid analgesic in the postoperative setting
    Ginsberg, B
    Sinatra, RS
    Adler, LJ
    Crews, JC
    Hord, AH
    Laurito, CE
    Ashburn, MA
    PAIN MEDICINE, 2003, 4 (01) : 31 - 38
  • [24] Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study
    Schaffer, Andrea L.
    Karanges, Emily A.
    Buckley, Nicholas A.
    Wilson, Andrew
    Degenhardt, Louisa
    Larance, Briony
    Pearson, Sallie-Anne
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (01) : 97 - 105
  • [25] Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study
    Portenoy, Russell K.
    Farrar, John T.
    Backonja, Misha-Miroslav
    Cleeland, Charles S.
    Yang, Kaity
    Friedman, Michael
    Colucci, Salvatore V.
    Richards, Patricia
    CLINICAL JOURNAL OF PAIN, 2007, 23 (04) : 287 - 299
  • [26] Efficacy and Tolerability of Oxycodone Hydrochloride Controlled-Release Tablets in Moderate to Severe Cancer Pain
    Hongming Pan
    Zaiyun Zhang
    Yiping Zhang
    Nong Xu
    Liqin Lu
    Chunfeng Dou
    Yong Guo
    Shixiu Wu
    Jianhua Yue
    Dongping Wu
    Yuechu Dai
    Clinical Drug Investigation, 2007, 27 : 259 - 267
  • [27] Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial
    Zecca, Ernesto
    Brunelli, Cinzia
    Bracchi, Paola
    Biancofiore, Giuseppe
    De Sangro, Carlo
    Bortolussi, Roberto
    Montanari, Luigi
    Maltoni, Marco
    Moro, Cecilia
    Colonna, Ugo
    Finco, Gabriele
    Roy, Maria Teresa
    Ferrari, Vittorio
    Alabiso, Oscar
    Rosti, Giovanni
    Kaasa, Stein
    Caraceni, Augusto
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 52 (06) : 783 - +
  • [28] Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain
    Hale, ME
    Fleischmann, R
    Salzman, R
    Wild, J
    Iwan, T
    Swanton, RE
    Kaiko, RF
    Lacouture, PG
    CLINICAL JOURNAL OF PAIN, 1999, 15 (03) : 179 - 183
  • [29] Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers
    Ladebo, Louise
    Foster, David J. R.
    Abuhelwa, Ahmad Y.
    Upton, Richard N.
    Kongstad, Kenneth T.
    Drewes, Asbjorn M.
    Christrup, Lona L.
    Olesen, Anne E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 126 (03) : 263 - 276
  • [30] Therapie chronischer Schmerzen mit oralem retardiertem OxycodonBehandlungsdaten von 4196 Patienten Oral controlled-release oxycodone for the treatment of chronic painData from 4196 patients
    J. Gaertner
    M. Frank
    B. Bosse
    R. Sabatowski
    F. Elsner
    T. Giesecke
    L. Radbruch
    Der Schmerz, 2006, 20 (1) : 61 - 68